nach oben

Erschienen in:

01.10.2011 | Original Article

Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)

verfasst von: Aminah Jatoi, Shaker R. Dakhil, Jeff A. Sloan, John W. Kugler, Kendrith M. Rowland Jr., Paul L. Schaefer, Paul J. Novotny, Donald B. Wender, Howard M. Gross, Charles L. Loprinzi

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Previous studies suggest tetracycline and other antibiotics lessen the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash. This study sought to confirm such findings.

Methods

Patients starting an EGFR inhibitor were eligible for this randomized, double-blinded, placebo-controlled study and had to be rash-free. They were then randomly assigned to tetracycline 500 mg orally twice a day for 28 days versus a placebo. Rash development and severity (monthly physician assessment and weekly patient-reported questionnaires), quality of life (SKINDEX-16), and adverse events were monitored during the 4-week intervention and then for an additional 4 weeks. The primary objective was to compare the incidence of grade 2 or worse rash between study arms; 32 patients per group provided a 90% probability of detecting a 40% difference in incidence with a type I error rate of 0.05 (two-sided).

Results

Sixty-five patients were enrolled, and groups were balanced on baseline characteristics. During the first 4 weeks, healthcare provider-reported data found that 27 tetracycline-treated patients (82%) and 24 placebo-exposed patients (75%) developed a rash. This rash was a grade 2+ in 17 (52%) and 14 (44%), respectively (p = 0.62). Comparable grade 2+ rash rates were observed during weeks 5 through 8 as well as with patient-reported rash data throughout the study period. Quality of life was comparable across study arms, and tetracycline was well tolerated.

Conclusion

Although previous studies suggest otherwise, this randomized, double-blinded, placebo-controlled study did not find that tetracycline lessened rash incidence or severity in patients who were taking EGFR inhibitors.

Shepherd FA, Rodriques Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123–132PubMedCrossRef

Saltz LB, Meropol NJ, Loehrer PJ et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208PubMedCrossRef

Jatoi A, Nguyen PL (2008) Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 3:1201–1204CrossRef

Wagner LI, Lacouture ME (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology 21(suppl 5):34–36PubMed

Jatoi A, Rowland K, Sloan JA et al (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced rashes: results from a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113:847–853PubMedCrossRef

Scope A, Agero AL, Dusza SW et al (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25:5390–5396PubMedCrossRef

Chren MM, Lasek RJ, Sahay AP, Sands LP (2001) Measurement properties of Skindex-16: a brief quality of life measure for patients with skin diseases. J Cutan Med Surg 5:105–110PubMedCrossRef

Gammon WR, Meyer C, Lantis S et al (1986) Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris: a double blind study. J Am Acad Dermatol 14:183–186PubMedCrossRef

Meynadier J, Alirezai M (1998) Systemic antibiotics for acne. Dermatology 196:135–139PubMedCrossRef

10.

Li J, Peccerillo J, Kaley K, Saif MW (2009) Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP 10:338–340PubMed

11.

Cholongitas E, Pipili C, Ioannidou D (2009) Malassezia folliculitis presented as acneiform eruption alter cetuximab administration. J Drugs Dermatol 8:274–275PubMed

12.

Grenader T, Gipps M, Goldberg A (2008) Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 9:59–60PubMedCrossRef

13.

Mitchell EP, Lacouture M, Shearer H et al (2009) Final STEPP results of the prophylactic versus reactive skin toxicity treatment for panitumumab-related skin toxicity in patients with metastatic colorectal cancer. J Clin Oncol 27:18s, supplement; abstract CRA4027CrossRef

Titel: Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)
verfasst von: Aminah Jatoi
Shaker R. Dakhil
Jeff A. Sloan
John W. Kugler
Kendrith M. Rowland Jr.
Paul L. Schaefer
Paul J. Novotny
Donald B. Wender
Howard M. Gross
Charles L. Loprinzi
Publikationsdatum: 01.10.2011
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 10/2011
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-010-0988-5

Springer Medizin

Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)